A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine.

Abstract

Hepatitis A and B are two of the most common vaccine-preventable liver diseases and continue to be a significant cause of morbidity and mortality worldwide, with their severity related to the individual's age upon initial infection. Twinrix (GlaxoSmithKline), a combined vaccine providing protection against both hepatitis A and B, has been available in more than 72 countries worldwide since 1997. This paper provides a critical review of clinical data on the efficacy, immunogenicity and tolerability of the combined vaccine, with particular focus on the clinical benefits of dual vaccination.

• Authors: Pierre Van Damme, Koen Van Herck
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 3 Issue 3 Pg. 249-67 (Jun 2004) ISSN: 1476-0584 [Print] England
• PMID: 15176942 (Publication Type: Journal Article, Review)

Chemical References

• Hepatitis A Vaccines
• Hepatitis Antibodies
• Hepatitis B Vaccines
• Vaccines, Combined
• twinrix

Topics

• Clinical Trials as Topic
• Hepatitis A (immunology, prevention & control)
• Hepatitis A Vaccines (administration & dosage, adverse effects, immunology)
• Hepatitis Antibodies (blood)
• Hepatitis B (immunology, prevention & control)
• Hepatitis B Vaccines (administration & dosage, adverse effects, immunology)
• Humans
• Immunization Schedule
• Vaccines, Combined (administration & dosage, immunology)